Global

Company Overview
TG ImmunoPharma (TGI)  is a biotech company focusing on the discovery of novel targets and development of antibodies or their analogs such as BsAb (or TsAb) and immunocytokine to harness the body's immune system in the frontline against tumor, viral infection and other diseases.
Company Overview
Our Journey

Click timeline or arrow to view more

Science
  • TG ImmunoPharma (TGI) works on an innovative immunotherapeutic approach against cancer.
  • This treatment model aims at restoring or renormalizing the defense, surveillance and homeostasis of immune system. Evidences have demonstrated that immunotherapy could lead to durable efficacy or even complete cure in some patients who have failed all available conventional therapies.
Technology
  • Top Scientific Team and Technology Platform
  • Global Leading Team in the Research of NK Cell/ILCs and Tumor Immunology
  • Deep Understanding of NK Cell Recognition and Their Receptors/Ligands
  • Cutting-edge Technology Platform named ABC-NKer®
News
TG ImmunoPharma (TGI) announces FDA clearance of IND application for TGI-2, a novel anti-PVRIG therapeutic antibody
2022.12.17

TG ImmunoPharma (TGI) announces FDA clearance of IND application for TGI-2, a novel anti-PVRIG therapeutic antibody

view more
×


Hefei TG ImmunoPharma Co., Ltd.

Our location: #6 Intelligent Science and Technology Park, Jingkai District, Hefei, Anhui, China

Telephone: 0551-62861151

Email: contact@tgimmunopharma.com



WeChat

ICP备字：皖ICP备2022011087号-1 （皖）-非经营性-2022-0075 皖公网安备 34019102001077号 ©Copyright by TGI All rights reserved.

网站技术支持：网新科技

Legal Statement Privacy Policy Terms Of Use